Loading…
Patch tests in non‐immediate cutaneous adverse drug reactions: Late readings on Day 4 is more sensitive than on Day 3
Background Patch tests (PTs) are recommended to identify the culprit drug in non‐immediate cutaneous adverse drug reactions (NICADRs). We recently reported that, in patients with NICADRs, a unique reading of PTs at day (D)2 compared with an additional second late reading at D4 missed almost half (45...
Saved in:
| Published in: | Contact dermatitis 2024-10, Vol.91 (4), p.321-326 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c2434-d84f03a79232ba6de6a1aeb8fd0725d50e93a473242246ff247087b3cce4199f3 |
| container_end_page | 326 |
| container_issue | 4 |
| container_start_page | 321 |
| container_title | Contact dermatitis |
| container_volume | 91 |
| creator | Matei, Ilaria Bettuzzi, Thomas Weill, Amandine Gener, Gwendeline Hareth, Kamar Bel Margaux, Fleck Verlinde‐Carvalho, Muriel Paul, Muriel Ingen‐Housz‐Oro, Saskia Assier, Haudrey |
| description | Background
Patch tests (PTs) are recommended to identify the culprit drug in non‐immediate cutaneous adverse drug reactions (NICADRs). We recently reported that, in patients with NICADRs, a unique reading of PTs at day (D)2 compared with an additional second late reading at D4 missed almost half (45.3%) of the positive PTs.
Objectives
To assess the change in sensitivity of the PT reading on D4 compared with the reading on D3.
Methods
We performed a retrospective (July 2020–June 2023) monocentric study of patients who had PTs with two readings for a NICADR. We compared reading on D3 and the second reading on D4 for the suspected drug (primary outcome) and for the related drugs tested simultaneously (secondary outcome).
Results
During the study period, 249 patients underwent patch testing with D3 and D4 readings. Regarding the primary outcome, the first reading at D3 was positive for 13.7% of patients, and the reading at D4 for 24.9% of patients (p |
| doi_str_mv | 10.1111/cod.14654 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3086066516</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3086066516</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2434-d84f03a79232ba6de6a1aeb8fd0725d50e93a473242246ff247087b3cce4199f3</originalsourceid><addsrcrecordid>eNp1kc9O3DAQxq2Kqiy0h75AZYlLOQTGf-Ik3NBS2kor0UN7trz2BIw2NtgJaG99hD4jT4Ih0EOlzmU0mp8-zTcfIR8ZHLFSxza6IyZVLd-QBVMAFdRC7ZAFMKgr1jZil-zlfA3AlOTtO7IrOmhaBnJB7n-Y0V7REfOYqQ80xPDw-48fBnTejEjtNJqAccrUuDtMGalL0yVNaOzoY8gndPWEldn5cJlpDPTMbKmkPtMhJqQZQ_ajv0M6XpnwuhfvydvebDJ-eOn75Nf5l5_Lb9Xq4uv35emqslwKWblW9iBM03HB10Y5VIYZXLe9g4bXrgbshJGN4JJzqfqeywbaZi2sRcm6rhf75POse5Pi7VRc6sFni5vN7EoLaBUoVTNV0IN_0Os4pVCu04LxrmOtVF2hDmfKpphzwl7fJD-YtNUM9FMauqShn9Mo7KcXxWldHvqXfH1_AY5n4N5vcPt_Jb28OJslHwFekZNe</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3129918469</pqid></control><display><type>article</type><title>Patch tests in non‐immediate cutaneous adverse drug reactions: Late readings on Day 4 is more sensitive than on Day 3</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Matei, Ilaria ; Bettuzzi, Thomas ; Weill, Amandine ; Gener, Gwendeline ; Hareth, Kamar Bel ; Margaux, Fleck ; Verlinde‐Carvalho, Muriel ; Paul, Muriel ; Ingen‐Housz‐Oro, Saskia ; Assier, Haudrey</creator><creatorcontrib>Matei, Ilaria ; Bettuzzi, Thomas ; Weill, Amandine ; Gener, Gwendeline ; Hareth, Kamar Bel ; Margaux, Fleck ; Verlinde‐Carvalho, Muriel ; Paul, Muriel ; Ingen‐Housz‐Oro, Saskia ; Assier, Haudrey</creatorcontrib><description>Background
Patch tests (PTs) are recommended to identify the culprit drug in non‐immediate cutaneous adverse drug reactions (NICADRs). We recently reported that, in patients with NICADRs, a unique reading of PTs at day (D)2 compared with an additional second late reading at D4 missed almost half (45.3%) of the positive PTs.
Objectives
To assess the change in sensitivity of the PT reading on D4 compared with the reading on D3.
Methods
We performed a retrospective (July 2020–June 2023) monocentric study of patients who had PTs with two readings for a NICADR. We compared reading on D3 and the second reading on D4 for the suspected drug (primary outcome) and for the related drugs tested simultaneously (secondary outcome).
Results
During the study period, 249 patients underwent patch testing with D3 and D4 readings. Regarding the primary outcome, the first reading at D3 was positive for 13.7% of patients, and the reading at D4 for 24.9% of patients (p < 0.0001). Regarding the secondary outcome, only 9.6% of patients had all their positive PT at D3 compared with 24.9% of patients at D4 (p < 0.0001). Considering the evaluated drug classes, no statistical difference was observed. However, we highlight that D3 reading detected all positive carbamazepine PTs (n = 3) while positive clindamycin PTs (n = 4) were identified only with the help of the second reading on D4.
Conclusion
This study showed that, an additional D4 reading compared with a single D3 reading enhanced the sensitivity of PTs to identify culprit drugs and related. Further studies should replicate these findings and evaluate the medico‐economic balance and safety of a single reading of PTs on D4.
Our study shows that a second reading at D4 (24.9%) enchances the sensitivity of a first reading at D3 (13.7%) for the patients' positivity of PTs with suspect drugs in the exploration of NICADR (p < 0.0001). Late readings should not be carried out on D3 because of an important loss of sensibility compared to D4.</description><identifier>ISSN: 0105-1873</identifier><identifier>ISSN: 1600-0536</identifier><identifier>EISSN: 1600-0536</identifier><identifier>DOI: 10.1111/cod.14654</identifier><identifier>PMID: 39078104</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; adverse drug reactions ; Aged ; Carbamazepine ; Clindamycin ; cross‐reactions ; Drug development ; Drug Eruptions - diagnosis ; Drug Eruptions - etiology ; epidemiology ; Female ; Humans ; Male ; Middle Aged ; Patch Tests ; Retrospective Studies ; Sensitivity analysis ; Sensitivity and Specificity ; Side effects ; Time Factors</subject><ispartof>Contact dermatitis, 2024-10, Vol.91 (4), p.321-326</ispartof><rights>2024 The Author(s). published by John Wiley & Sons Ltd.</rights><rights>2024 The Author(s). Contact Dermatitis published by John Wiley & Sons Ltd.</rights><rights>2024. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2434-d84f03a79232ba6de6a1aeb8fd0725d50e93a473242246ff247087b3cce4199f3</cites><orcidid>0009-0003-0627-3181 ; 0000-0002-5613-2745</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39078104$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Matei, Ilaria</creatorcontrib><creatorcontrib>Bettuzzi, Thomas</creatorcontrib><creatorcontrib>Weill, Amandine</creatorcontrib><creatorcontrib>Gener, Gwendeline</creatorcontrib><creatorcontrib>Hareth, Kamar Bel</creatorcontrib><creatorcontrib>Margaux, Fleck</creatorcontrib><creatorcontrib>Verlinde‐Carvalho, Muriel</creatorcontrib><creatorcontrib>Paul, Muriel</creatorcontrib><creatorcontrib>Ingen‐Housz‐Oro, Saskia</creatorcontrib><creatorcontrib>Assier, Haudrey</creatorcontrib><title>Patch tests in non‐immediate cutaneous adverse drug reactions: Late readings on Day 4 is more sensitive than on Day 3</title><title>Contact dermatitis</title><addtitle>Contact Dermatitis</addtitle><description>Background
Patch tests (PTs) are recommended to identify the culprit drug in non‐immediate cutaneous adverse drug reactions (NICADRs). We recently reported that, in patients with NICADRs, a unique reading of PTs at day (D)2 compared with an additional second late reading at D4 missed almost half (45.3%) of the positive PTs.
Objectives
To assess the change in sensitivity of the PT reading on D4 compared with the reading on D3.
Methods
We performed a retrospective (July 2020–June 2023) monocentric study of patients who had PTs with two readings for a NICADR. We compared reading on D3 and the second reading on D4 for the suspected drug (primary outcome) and for the related drugs tested simultaneously (secondary outcome).
Results
During the study period, 249 patients underwent patch testing with D3 and D4 readings. Regarding the primary outcome, the first reading at D3 was positive for 13.7% of patients, and the reading at D4 for 24.9% of patients (p < 0.0001). Regarding the secondary outcome, only 9.6% of patients had all their positive PT at D3 compared with 24.9% of patients at D4 (p < 0.0001). Considering the evaluated drug classes, no statistical difference was observed. However, we highlight that D3 reading detected all positive carbamazepine PTs (n = 3) while positive clindamycin PTs (n = 4) were identified only with the help of the second reading on D4.
Conclusion
This study showed that, an additional D4 reading compared with a single D3 reading enhanced the sensitivity of PTs to identify culprit drugs and related. Further studies should replicate these findings and evaluate the medico‐economic balance and safety of a single reading of PTs on D4.
Our study shows that a second reading at D4 (24.9%) enchances the sensitivity of a first reading at D3 (13.7%) for the patients' positivity of PTs with suspect drugs in the exploration of NICADR (p < 0.0001). Late readings should not be carried out on D3 because of an important loss of sensibility compared to D4.</description><subject>Adult</subject><subject>adverse drug reactions</subject><subject>Aged</subject><subject>Carbamazepine</subject><subject>Clindamycin</subject><subject>cross‐reactions</subject><subject>Drug development</subject><subject>Drug Eruptions - diagnosis</subject><subject>Drug Eruptions - etiology</subject><subject>epidemiology</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Patch Tests</subject><subject>Retrospective Studies</subject><subject>Sensitivity analysis</subject><subject>Sensitivity and Specificity</subject><subject>Side effects</subject><subject>Time Factors</subject><issn>0105-1873</issn><issn>1600-0536</issn><issn>1600-0536</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp1kc9O3DAQxq2Kqiy0h75AZYlLOQTGf-Ik3NBS2kor0UN7trz2BIw2NtgJaG99hD4jT4Ih0EOlzmU0mp8-zTcfIR8ZHLFSxza6IyZVLd-QBVMAFdRC7ZAFMKgr1jZil-zlfA3AlOTtO7IrOmhaBnJB7n-Y0V7REfOYqQ80xPDw-48fBnTejEjtNJqAccrUuDtMGalL0yVNaOzoY8gndPWEldn5cJlpDPTMbKmkPtMhJqQZQ_ajv0M6XpnwuhfvydvebDJ-eOn75Nf5l5_Lb9Xq4uv35emqslwKWblW9iBM03HB10Y5VIYZXLe9g4bXrgbshJGN4JJzqfqeywbaZi2sRcm6rhf75POse5Pi7VRc6sFni5vN7EoLaBUoVTNV0IN_0Os4pVCu04LxrmOtVF2hDmfKpphzwl7fJD-YtNUM9FMauqShn9Mo7KcXxWldHvqXfH1_AY5n4N5vcPt_Jb28OJslHwFekZNe</recordid><startdate>202410</startdate><enddate>202410</enddate><creator>Matei, Ilaria</creator><creator>Bettuzzi, Thomas</creator><creator>Weill, Amandine</creator><creator>Gener, Gwendeline</creator><creator>Hareth, Kamar Bel</creator><creator>Margaux, Fleck</creator><creator>Verlinde‐Carvalho, Muriel</creator><creator>Paul, Muriel</creator><creator>Ingen‐Housz‐Oro, Saskia</creator><creator>Assier, Haudrey</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0003-0627-3181</orcidid><orcidid>https://orcid.org/0000-0002-5613-2745</orcidid></search><sort><creationdate>202410</creationdate><title>Patch tests in non‐immediate cutaneous adverse drug reactions: Late readings on Day 4 is more sensitive than on Day 3</title><author>Matei, Ilaria ; Bettuzzi, Thomas ; Weill, Amandine ; Gener, Gwendeline ; Hareth, Kamar Bel ; Margaux, Fleck ; Verlinde‐Carvalho, Muriel ; Paul, Muriel ; Ingen‐Housz‐Oro, Saskia ; Assier, Haudrey</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2434-d84f03a79232ba6de6a1aeb8fd0725d50e93a473242246ff247087b3cce4199f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>adverse drug reactions</topic><topic>Aged</topic><topic>Carbamazepine</topic><topic>Clindamycin</topic><topic>cross‐reactions</topic><topic>Drug development</topic><topic>Drug Eruptions - diagnosis</topic><topic>Drug Eruptions - etiology</topic><topic>epidemiology</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Patch Tests</topic><topic>Retrospective Studies</topic><topic>Sensitivity analysis</topic><topic>Sensitivity and Specificity</topic><topic>Side effects</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matei, Ilaria</creatorcontrib><creatorcontrib>Bettuzzi, Thomas</creatorcontrib><creatorcontrib>Weill, Amandine</creatorcontrib><creatorcontrib>Gener, Gwendeline</creatorcontrib><creatorcontrib>Hareth, Kamar Bel</creatorcontrib><creatorcontrib>Margaux, Fleck</creatorcontrib><creatorcontrib>Verlinde‐Carvalho, Muriel</creatorcontrib><creatorcontrib>Paul, Muriel</creatorcontrib><creatorcontrib>Ingen‐Housz‐Oro, Saskia</creatorcontrib><creatorcontrib>Assier, Haudrey</creatorcontrib><collection>Wiley-Blackwell Titles (Open access)</collection><collection>Wiley Free Archive</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Contact dermatitis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matei, Ilaria</au><au>Bettuzzi, Thomas</au><au>Weill, Amandine</au><au>Gener, Gwendeline</au><au>Hareth, Kamar Bel</au><au>Margaux, Fleck</au><au>Verlinde‐Carvalho, Muriel</au><au>Paul, Muriel</au><au>Ingen‐Housz‐Oro, Saskia</au><au>Assier, Haudrey</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Patch tests in non‐immediate cutaneous adverse drug reactions: Late readings on Day 4 is more sensitive than on Day 3</atitle><jtitle>Contact dermatitis</jtitle><addtitle>Contact Dermatitis</addtitle><date>2024-10</date><risdate>2024</risdate><volume>91</volume><issue>4</issue><spage>321</spage><epage>326</epage><pages>321-326</pages><issn>0105-1873</issn><issn>1600-0536</issn><eissn>1600-0536</eissn><abstract>Background
Patch tests (PTs) are recommended to identify the culprit drug in non‐immediate cutaneous adverse drug reactions (NICADRs). We recently reported that, in patients with NICADRs, a unique reading of PTs at day (D)2 compared with an additional second late reading at D4 missed almost half (45.3%) of the positive PTs.
Objectives
To assess the change in sensitivity of the PT reading on D4 compared with the reading on D3.
Methods
We performed a retrospective (July 2020–June 2023) monocentric study of patients who had PTs with two readings for a NICADR. We compared reading on D3 and the second reading on D4 for the suspected drug (primary outcome) and for the related drugs tested simultaneously (secondary outcome).
Results
During the study period, 249 patients underwent patch testing with D3 and D4 readings. Regarding the primary outcome, the first reading at D3 was positive for 13.7% of patients, and the reading at D4 for 24.9% of patients (p < 0.0001). Regarding the secondary outcome, only 9.6% of patients had all their positive PT at D3 compared with 24.9% of patients at D4 (p < 0.0001). Considering the evaluated drug classes, no statistical difference was observed. However, we highlight that D3 reading detected all positive carbamazepine PTs (n = 3) while positive clindamycin PTs (n = 4) were identified only with the help of the second reading on D4.
Conclusion
This study showed that, an additional D4 reading compared with a single D3 reading enhanced the sensitivity of PTs to identify culprit drugs and related. Further studies should replicate these findings and evaluate the medico‐economic balance and safety of a single reading of PTs on D4.
Our study shows that a second reading at D4 (24.9%) enchances the sensitivity of a first reading at D3 (13.7%) for the patients' positivity of PTs with suspect drugs in the exploration of NICADR (p < 0.0001). Late readings should not be carried out on D3 because of an important loss of sensibility compared to D4.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>39078104</pmid><doi>10.1111/cod.14654</doi><tpages>6</tpages><orcidid>https://orcid.org/0009-0003-0627-3181</orcidid><orcidid>https://orcid.org/0000-0002-5613-2745</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0105-1873 |
| ispartof | Contact dermatitis, 2024-10, Vol.91 (4), p.321-326 |
| issn | 0105-1873 1600-0536 1600-0536 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3086066516 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Adult adverse drug reactions Aged Carbamazepine Clindamycin cross‐reactions Drug development Drug Eruptions - diagnosis Drug Eruptions - etiology epidemiology Female Humans Male Middle Aged Patch Tests Retrospective Studies Sensitivity analysis Sensitivity and Specificity Side effects Time Factors |
| title | Patch tests in non‐immediate cutaneous adverse drug reactions: Late readings on Day 4 is more sensitive than on Day 3 |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T10%3A32%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Patch%20tests%20in%20non%E2%80%90immediate%20cutaneous%20adverse%20drug%20reactions:%20Late%20readings%20on%20Day%204%20is%20more%20sensitive%20than%20on%20Day%203&rft.jtitle=Contact%20dermatitis&rft.au=Matei,%20Ilaria&rft.date=2024-10&rft.volume=91&rft.issue=4&rft.spage=321&rft.epage=326&rft.pages=321-326&rft.issn=0105-1873&rft.eissn=1600-0536&rft_id=info:doi/10.1111/cod.14654&rft_dat=%3Cproquest_cross%3E3086066516%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2434-d84f03a79232ba6de6a1aeb8fd0725d50e93a473242246ff247087b3cce4199f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3129918469&rft_id=info:pmid/39078104&rfr_iscdi=true |